Abiopharma

🔍 Stevens Charles K. III (Director)

Company: FLEX LTD. (FLEX)

Report Date: 2026-08-05

Detailed Transactions and Holdings:

• Acquired 1,928 shares of Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 47,354.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,230 shares of Ordinary Shares (Direct)
  Date: 2026-08-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 48,584.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: On August 5, 2026, the Reporting Person was awarded a total of 1,928 restricted share units ("RSUs") pursuant to the terms of the annual equity award to Non-Employee Directors under the Issuer's Amended and Restated 2017 Equity Incentive Plan as more fully described in the section titled "Fiscal Year 2026 Non-Employee Directors' Compensation" beginning on page 24 of the Issuer's Proxy Statement filed with the SEC on June 24, 2026. Each RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not previously forfeited. The award shall vest in full on the date immediately prior to the date of the Issuer's 2027 annual general meeting.
• F2: On August 5, 2026, the Reporting Person received a one-time special compensation equity award consisting of RSUs having an aggregate value of $150,000 which shall vest in full on the date immediately prior to the date of the Issuer's 2027 annual general meeting. Each unvested RSU represents a contingent right to receive one unrestricted, fully transferrable share for each vested RSU which has not been previously forfeited.
• F3: Includes 3,158 unvested RSUs, which will shall vest in full on the date immediately prior to the date of the Issuer's 2027 annual general meeting. Each unvested RSU represents a contingent right to receive one unrestricted, fully transferrable share for each vested RSU which has not been previously forfeited.